![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » ROCHE SNAPS UP BIOTECH FIRM GLYCART
ROCHE SNAPS UP BIOTECH FIRM GLYCART
July 19, 2005
The Roche pharmaceuticals group is acquiring a Swiss developer of biotech cancer drugs, GlycArt, for about SFr235 million ($180.2 million). The deal is seen as boosting Roche's position as the world's leading producer of cancer medicines. GlycArt Biotechnology of Schlieren near Zurich is a privately owned biotech company which has three monoclonal antibody drugs in preclinical testing. Such antibodies are mass-produced artificial versions of the proteins made by the immune system that seek out and destroy specific targets.
Swissinfo
(http://www.swissinfo.org/sen/swissinfo.html?siteSect=161&sid=5952348&cKey=1121766728000)
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
21Oct